A polypeptide nanodrug capable of inducing necroptosis and autophagy-related synergistic apoptosis, and a preparation method and application thereof
By designing a peptide nanodrug RDP that responds to both Caspase-3 and GSH, RIPK3 aggregation was activated, achieving efficient drug release and activation of the necrosis-apoptosis pathway in tumor cells. This solved the problem of anti-apoptosis mechanism in tumor cells in traditional anti-cancer therapy and significantly inhibited the growth of colorectal cancer.
CN122103266APending Publication Date: 2026-05-29NANKAI UNIV
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- NANKAI UNIV
- Filing Date
- 2026-01-09
- Publication Date
- 2026-05-29
Smart Images
Figure CN122103266A_ABST
Abstract
The present application belongs to the technical field of biomedical materials and nano drugs, and discloses a polypeptide nano drug capable of inducing necrosis and autophagy related synergistic apoptosis and a preparation method and application thereof. X-DDP1 and DDP1 are self-assembled to form a responsive polypeptide nano drug, which provides a delivery platform for broad-spectrum chemotherapy drugs such as buforin RBG, irinotecan CPT11 or camptothecin CPT, realizes a Caspase-3 / GSH double-response mechanism, improves drug release specificity and spatial controllability, can promote RIPK3 aggregation and activate necrotic apoptosis in cells, can effectively inhibit the growth of cancer, and has potential clinical application value.
Need to check novelty before this filing date? Find Prior Art